MedTrace Logo

Post-activation Potentiation and Sprinting Performance

NCT06619899 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-12-04

No results posted yet for this study

Summary

Scientific data regarding the post-activation potentiation (PAP) phenomenon on sprinting performance is scarce, especially regarding the effect of performing pre-conditioning power exercises on subsequent sprinting performance. Additionally, there is no data regarding the rate of fatigue onset when power pre-conditioning exercise before sprints are performed repeatedly at the same training session. This research will provide important information to coaches and athletes for the design of an optimum training program for the maximization of the athletes' performance and the avoidance of injuries.

Conditions

  • Sprint Performance

Interventions

OTHER

PAP exercise with 0% body mass

The participants will perform 6 x 30m sprints. Before each sprint they will perform 2 x 4 countermovement jumps with 0% body mass.

OTHER

PAP exercise with 20% body mass

Description: The participants will perform 6 x 30m sprints. Before each sprint they will perform 2 x 4 countermovement jumps with 0% body mass

OTHER

No PAP exercise

No PAP exercise will be performed. The participants will perform only 6 x 30m sprints.

Sponsors & Collaborators

  • University of Thessaly

    lead OTHER

Principal Investigators

  • Chariklia K Deli, Associate Professor · University of Thessaly

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2024-11-15
Completion
2024-11-15

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06619899 on ClinicalTrials.gov